Lytix Biopharma today announces the appointment of Karsten Bruins Slot as Director Clinical Development, providing scientific and clinical guidance to cross-functional teams and colleagues
Most recently Karsten Bruins Slot served as ‘Medical Director – Head of Oncology’ in Nykode Therapeutics.
Karsten Bruins Slot has his MD from University of Groningen, The Netherlands, and received his doctorate at Oslo University Hospital in 2009. The same year he joined The Norwegian Medicines Agency, where he was Norway's representative in the CHMP - EU's scientific expert panel for the approval of medicinal products. In May 2017, he moved to the pharmaceutical industry and started at Roche as Country Medical Manager. Two years later he was promoted to Medical Director and stayed in that position until he joined Nykode in August 2021.
“We are very happy to welcome Karsten to our team”, says Øystein Rekdal, CEO of Lytix. “Karsten brings with him valuable experience from clinical work both in biotech and big pharma as well as regulatory experience”.
Karsten Bruins Slot enters his position at Lytix today, March 22nd, 2023, and his focus ahead will be the ongoing ATLAS-IT-05 study and the preparations for the Phase I study ATLAS-IT-06 with LTX-401, Lytix’ second molecule to enter the clinic.
“To participate in the development of new types of immunotherapies for cancer patients is at my heart. At Lytix I find an opportunity to be at the forefront of immuno-oncology and contribute to bringing new treatment options to cancer patients,” says Karsten Bruins Slot.
